Why the study?
Quality of anticoagulation measured by time in therapeutic range (TTR) is less often evaluated despite significant clinical implications, prompting evaluation of TTR and adverse events in a district-level hospital setting.
Real-world warfarin management in a community hospital setting showed poor time in therapeutic range and high rates of adverse events for patients with AF and prosthetic heart valves.
Answers are grounded in this paper and cite their sources.
Highlights challenges in warfarin management for AF and PHV; hypothesis-generating for trials of alternative anticoagulants.
Background: Two common indications for oral anticoagulants are patients with non-valvular atrial fibrillation (AF) or prosthetic heart valves (PHV). The degree of anticoagulation is monitored by evaluating the international normalised ratio (INR); however, the quality of anticoagulation, determined by the time in therapeutic range (TTR), is less often evaluated. TTR has significant clinical implications in patient outcomes. Objectives: We sought to identify the indications for anticoagulation and determine its quality via the TTR at a single centre, community-based and district level hospital in the setting of usual care. We documented the prevalence of thrombo-embolic and haemorrhagic adverse events and we also collected data on factors that may contribute to a poor TTR or increased risk of adverse events. Methods: We conducted a retrospective, descriptive and observational study with chart audits evaluating the anticoagulation indication and control for the preceding 1 year for each patient. Descriptive statistics included mean and standard deviation for quantitative data and frequencies for categorical data. Chi-square tests were used to analyse comparisons of categorical data and the student’s t-test for continuous variables. Two-tailed p-values less than 0.05 were considered significant. Results: TTR was poor for patients with AF and PHV (44.5% and 13.7% respectively). We identified older age, less frequent testing and high target ranges as significant factors associated with poorer outcomes. We demonstrated a high prevalence of adverse events (25.4%). Conclusion: Patients in this setting demonstrated poor quality of anticoagulation and had a high prevalence of adverse events.
No takes yet. Share an insight, caveat, or question.
Sadhabariss et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: